Breaking News Instant updates and real-time market news.

MRK

Merck

16:16
06/12/17
06/12
16:16
06/12/17
16:16

Merck issues update on two Keytruda studies, says pauses enrollment

Merck provided an update on two combination studies of KEYTRUDA, the company's anti-PD-1 therapy, in the blood cancer multiple myeloma. Merck has accepted the external Data Monitoring Committee recommendation to pause new enrollment on KEYNOTE-183 and KEYNOTE-185, two studies exploring KEYTRUDA treatment in combination with other therapies in multiple myeloma. "The pause is to allow for additional information to be collected to better understand more reports of death in the KEYTRUDA groups," the company said. Patients currently enrolled in these two studies will continue to receive treatment. Other studies of KEYTRUDA continue unchanged. KEYNOTE-183 is a Phase 3 study comparing pomalidomide and low-dose dexamethasone with KEYTRUDA to pomalidomide and low-dose dexamethasone alone in patients with refractory or relapsed and refractory multiple myeloma who have undergone at least 2 lines of prior treatment. KEYNOTE-185 is a Phase 3 study comparing lenalidomide and low-dose dexamethasone with KEYTRUDA to lenalidomide and low-dose dexamethasone alone in patients with newly diagnosed and treatment-naive multiple myeloma who are ineligible for autologous stem cell transplant.

  • 14

    Jun

  • 22

    Sep

MRK Merck

05/22/17
ADAM
05/22/17
NO CHANGE
Target $85
ADAM
Buy
CV events 'may kill' Amgen's romosozumab development, says Canaccord
Canaccord analyst John Newman said Amgen (AMGN) and partner UCB's report of a higher rate of cardiovascular Serious Adverse Events for romosozumab in the Phase 3 ARCH study in osteoporosis suggests a much lower chance of FDA approval for the drug and may "kill" romosozumab's development. He notes that Merck's (MRK) cathepsin-K inhibitor was previously discontinued due to increased risk of atrial fibrillation and stroke. In addition to the safety signals, Newman points out that romosozumab was worse than Radius' (RDUS) Tymlos for non-vertebral fracture and for vertebral fracture, suggesting Radius' drug also has much better efficacy, said the analyst, who keeps a Buy rating and $85 price target on Radius Health shares, which are up $4.47, or 12.8%, to $39.40 in pre-market trading.
06/05/17
PIPR
06/05/17
NO CHANGE
PIPR
Piper views AstraZeneca, J&J as ASCO standouts
The standouts at ASCO over the weekend were the "compelling results" presented on Johnson & Johnson's (JNJ) Zytiga from the Latitude study in prostate cancer and AstraZeneca's (AZN) Lynparza in the OlympiAD trial in BRCA mutant breast cancer, Piper Jaffray analyst Richard Purkiss tells investors in a research note. In lung cancer, Merck's (MRK) updated data in KN021G "appears more promising" than Bristol-Myers' (BMY) updated data in CM012, the analyst adds. Purkiss believes, however, that relative to recent ASCOs, the data "so far in totality is underwhelming."
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/06/17
BMOC
06/06/17
NO CHANGE
BMOC
Incyte should be bought on recent weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya says that data on the combination of Bristol-Myers' (BMY) Opdivo and Incyte's (INCY) epacadostat "confirmed the benefit" seen in a previous study. The analyst says that the safety of Merck's (MRK) Keytruda in combination with epacadostat is better than the standard of care. He keeps a $166 price target and Outperform rating on Incyte.

TODAY'S FREE FLY STORIES

ESPR

Esperion

$44.74

-0.24 (-0.53%)

13:45
08/21/17
08/21
13:45
08/21/17
13:45
Hot Stocks
Breaking Hot Stocks news story on Esperion »

Meditor Group reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$18.12

-0.02 (-0.11%)

13:45
08/21/17
08/21
13:45
08/21/17
13:45
Options
KKR call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$133.44

0.805 (0.61%)

13:35
08/21/17
08/21
13:35
08/21/17
13:35
Periodicals
J&J must pay $417M in talc products trial, lawyers say, Reuters reports 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 05

    Sep

  • 06

    Sep

  • 22

    Sep

FJTSY

Fujitsu

$37.70

0.25 (0.67%)

, LNVGY

Lenovo

$11.52

-0.36 (-3.03%)

13:34
08/21/17
08/21
13:34
08/21/17
13:34
Periodicals
Fujitsu looking to sell mobile phone business, Nikkei reports »

Fujitsu's (FJTSY) is…

FJTSY

Fujitsu

$37.70

0.25 (0.67%)

LNVGY

Lenovo

$11.52

-0.36 (-3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ILMN

Illumina

$189.32

-1.88 (-0.98%)

13:25
08/21/17
08/21
13:25
08/21/17
13:25
Options
Illumina call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$83.85

0.441 (0.53%)

, COTY

Coty

$19.39

0.155 (0.81%)

13:23
08/21/17
08/21
13:23
08/21/17
13:23
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MDT

Medtronic

$83.85

0.441 (0.53%)

COTY

Coty

$19.39

0.155 (0.81%)

TOL

Toll Brothers

$38.29

0.14 (0.37%)

DSW

DSW

$15.74

-0.1 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 06

    Sep

  • 20

    Sep

ZAYO

Zayo Group

$32.88

-0.17 (-0.51%)

, NDSN

Nordson

$124.13

-1.37 (-1.09%)

13:22
08/21/17
08/21
13:22
08/21/17
13:22
Earnings
Notable companies reporting after market close »

Notable companies…

ZAYO

Zayo Group

$32.88

-0.17 (-0.51%)

NDSN

Nordson

$124.13

-1.37 (-1.09%)

PINC

Premier

$32.94

-0.15 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 06

    Sep

$NSD

NASDAQ Market Internals

13:17
08/21/17
08/21
13:17
08/21/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRZN

Horizon Technology

$10.27

-0.23 (-2.19%)

13:16
08/21/17
08/21
13:16
08/21/17
13:16
Upgrade
Horizon Technology rating change  »

Horizon Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
08/21/17
08/21
13:16
08/21/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$8.65

0.45 (5.49%)

13:15
08/21/17
08/21
13:15
08/21/17
13:15
Options
Sears put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$10.64

0.0763 (0.72%)

13:13
08/21/17
08/21
13:13
08/21/17
13:13
Periodicals
Union votes in favor of strike action at Ford Bridgend plant, Wales Online says »

The Unite union, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$32.31

-2.0701 (-6.02%)

13:11
08/21/17
08/21
13:11
08/21/17
13:11
Technical Analysis
Technical View: Foot Locker at new 52-week and multi-year lows »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CENX

Century Aluminum

$15.01

0.19 (1.28%)

13:09
08/21/17
08/21
13:09
08/21/17
13:09
Hot Stocks
Breaking Hot Stocks news story on Century Aluminum »

Balyasny Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOSBF

Toshiba, also use TOSYY

$2.69

-0.052 (-1.90%)

, TOSYY

Toshiba, also use TOSBF

$16.05

-0.32 (-1.95%)

13:08
08/21/17
08/21
13:08
08/21/17
13:08
Periodicals
Toshiba, Western Digital heads to seek compromise on memory unit, Nikkei says »

Western Digital (WDC) CEO…

TOSBF

Toshiba, also use TOSYY

$2.69

-0.052 (-1.90%)

TOSYY

Toshiba, also use TOSBF

$16.05

-0.32 (-1.95%)

WDC

Western Digital

$83.20

0.72 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCI

Johnson Controls

$37.86

0.81 (2.19%)

13:06
08/21/17
08/21
13:06
08/21/17
13:06
Recommendations
Johnson Controls analyst commentary  »

Johnson Controls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWL

Newell Brands

$48.44

-1.22 (-2.46%)

13:05
08/21/17
08/21
13:05
08/21/17
13:05
Options
Newell Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLAB

Mesa Labs

$129.98

-0.57 (-0.44%)

12:56
08/21/17
08/21
12:56
08/21/17
12:56
Hot Stocks
Mesa Labs director Stuart Campbell sells 2,000 shares »

Stuart Campbell, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

CSIQ

Canadian Solar

$16.63

0.23 (1.40%)

12:55
08/21/17
08/21
12:55
08/21/17
12:55
Options
Canadian Solar put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENRJ

EnerJex Resources

$0.28

-0.023 (-7.54%)

12:55
08/21/17
08/21
12:55
08/21/17
12:55
Hot Stocks
Breaking Hot Stocks news story on EnerJex Resources »

EnerJex Resources trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENRJ

EnerJex Resources

$0.28

-0.023 (-7.54%)

12:46
08/21/17
08/21
12:46
08/21/17
12:46
Hot Stocks
EnerJex Resources appoints Schleizer as interim CFO »

Effective August 17,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$8.11

-0.16 (-1.93%)

, AAPL

Apple

$157.50

-0.36 (-0.23%)

12:45
08/21/17
08/21
12:45
08/21/17
12:45
Periodicals
SEC reviewing Spotify's plan to skip IPO in NYSE listing, Bloomberg says »

Executives from music…

P

Pandora

$8.11

-0.16 (-1.93%)

AAPL

Apple

$157.50

-0.36 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 24

    Aug

  • 05

    Sep

COTY

Coty

$19.35

0.12 (0.62%)

12:45
08/21/17
08/21
12:45
08/21/17
12:45
Options
Coty call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

GPC

Genuine Parts

$82.19

0.59 (0.72%)

12:43
08/21/17
08/21
12:43
08/21/17
12:43
Hot Stocks
Genuine Parts elects Hardin as new independent director, adds 15M to repurchase »

Genuine Parts announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

12:40
08/21/17
08/21
12:40
08/21/17
12:40
Hot Stocks
Icahn Automotive announces growth plans in Detroit »

Icahn Automotive Group, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.